MADRIGAL PHARMACEUTICALS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $444.14 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-07-30
- MADRIGAL PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $437.68, a 27.94% increase year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $342.11, a 48.89% increase year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $229.77.
- MADRIGAL PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $340.27, a 44.92% increase from fiscal 2024.
- MADRIGAL PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $234.80, a 22.99% increase from fiscal 2023.
- MADRIGAL PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $190.91.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $444.14 10-Q · filed 2026-07-30 | |||
| 2026-03-31 | $437.68 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | $340.27 10-K · filed 2026-02-19 | |||
| 2025-09-30 | $331.34 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | $331.98 10-Q · filed 2025-08-05 | |||
| 2025-03-31 | $342.11 10-Q · filed 2025-05-01 | |||
| 2024-12-31 | $234.80 10-K · filed 2025-02-26 | |||
| 2024-09-30 | $234.84 10-Q · filed 2024-10-31 | |||
| 2024-06-30 | $232.88 10-Q · filed 2024-08-07 | |||
| 2024-03-31 | $229.77 10-Q · filed 2024-05-07 | |||
| 2023-12-31 | $190.91 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |